Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3
Abstract
A Bayesian approach with frequentist validity has been developed to support inferences derived from a “Level A” in vivo-in vitro correlation (IVIVC). Irrespective of whether the in vivo data reflect in vivo dissolution or absorption, the IVIVC is typically assessed using a linear regression model. Confidence intervals are generally used to describe the uncertainty around the model. While the confidence intervals can describe population-level variability, it does not address the individual-level variability. Thus, there remains an inability to define a range of individual-level drug concentration-time profiles across a population based upon the “Level A” predictions. This individual-level prediction is distinct from what can be accomplished by a traditional linear regression approach where the focus of the statistical assessment is at a marginal rather than an individual level. The objective of this study is to develop a hierarchical Bayesian method for evaluation of IVIVC, incorporating both the individual- and population-level variability, and to use this method to derive Bayesian tolerance intervals with matching priors that have frequentist validity in evaluating an IVIVC. In so doing, we can now generate population profiles that incorporate not only variability in subject pharmacokinetics but also the variability in the in vivo product performance.
Authors and Affiliations
Junshan Qiu, Marilyn Martinez, Ram Tiwari
Keywords
Related Articles
- EP ID EP680871
- DOI 10.1208/s12248-016-9880-7
- Views 67
- Downloads 0
Fmoc-Conjugated PEG-Vitamin E2 Micelles for Tumor-Targeted Delivery of Paclitaxel: Enhanced Drug-Carrier Interaction and Loading Capacity
The online version of this article (doi:10.1208/s12248-014-9651-2) contains supplementary material, which is available to authorized users.
Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis
Apoptosis is associated with cascades of biochemical changes, including caspase activation, cleavage of poly-ADP-ribose polymerase (PARP), and fragmentation of genomic DNA. Knowledge of the kinetics of these changes in d...
Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team
At the initiative of four regional professional organizations from Europe (European Bioanalysis Forum (EBF)) and North America (AAPS, Applied Pharmaceutical Analysis (APA) APA and Calibration & validation group (...
Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data
The online version of this article (doi:10.1208/s12248-012-9419-5) contains supplementary material, which is available to authorized users.
Emerging Technologies to Increase Ligand Binding Assay Sensitivity
Ligand binding assays (LBAs) have been the method of choice for protein analyte measurements for more than four decades. Over the years, LBA methods have improved in sensitivity and achieved larger dynamic ranges by usin...